Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATS29
2014-001295-65Phase 2Completed
- Sponsor
- TxCell
- Start
- Nov 2014
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Ovasave with Placebo (2 arms). Primary endpoint: CDAI response at Week 6. Started Nov 2014; status: completed.
02
Drugs
Ovasave
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-001295-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001295-65.